

Salubris is a USD-8-billion global integrated pharmaceutical group

dedicated to the research, development, manufacture, marketing, distribution, and service of professional pharmaceutical and medical products to bring healthier and happier life to people worldwide through world-leading quality and innovations.



Founded in 1998, 3500+ Employees, Stock code 002294

SALUBRIS

Mission Improving People's Lives with Exceptional Medicines

Vision Being the Most Influential Innovative Global Pharma

Values Keeping Promises is the Source of Happiness;

Focusing on Patient Needs;

Our Determination is Our Foundation.

6

**Innovative Pharmaceuticals
Approved & on the Market**



600+

**Active Patents
Worldwide**

3

**Patent Gold
Awards**

800+

**R&D Team
Professionals**

Innovation,

Chemical Drug
Innovation Projects

60

Biological Drug
Innovation Projects

19

Medical Device
Innovation Projects

12



Baoan API & FDF Productions
Brazil ANVISA approved



Beijing Coronary Artery Stent
Development Platform



Dayawan API & OSD Formulation Production
EU GMP Approved, US FDA GMP 2026

Quality &



Chengdu High-end &
Innovative Biologicals
Development Platform



Pingshan Lyophilized
Injection & Medical Device
Brazil ANVISA approved



Shandong
API & Intermediates production
EU GMP 2025



Suzhou
High-end Biologicals Site



Suzhou
Medical Equipment Industrial
Base

i Innovative Chemical & Biological Drugs

b Biosimilar Formulation

c Chemical Generic Formulation

a API & Intermediates

d Medical Devices

m CDMO/CMO



Extensive & Deep Marketing Network

We serve clients from **40+** countries
and regions around the world

You



Serving people in
health and sickness



Working with partners
and regulators



Advancing knowledge
with professionals



Caring for employees



Donating USD100million+
to humanitarian causes